Ozempic (semaglutide SC once-weekly) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 12 Diseases   138 Trials   138 Trials   3994 News 


12345678910111213...3940»
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Review, Journal:  The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review. (Pubmed Central) -  Sep 21, 2024   
    In further experiments using animal models of nerve crush injury, specimens given GLP-1 agonists reported a significant increase in the rate and density of nerve regeneration compared to controls. Thus, GLP-1 agonists show promise as both prophylactic and symptomatic treatment for MS and may provide further utility in the treatment of other autoimmune, inflammatory, and neurodegenerative conditions.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal, Real-world evidence, Real-world:  Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration-A Danish Cohort Study. (Pubmed Central) -  Sep 20, 2024   
    Thus, GLP-1 agonists show promise as both prophylactic and symptomatic treatment for MS and may provide further utility in the treatment of other autoimmune, inflammatory, and neurodegenerative conditions. Real-world semaglutide users generally resembled trial participants, but few follow the dose titration schemes tested in premarket clinical trials.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    New P3 trial:  Semaglutide in Treatment of Obesity (clinicaltrials.gov) -  Sep 19, 2024   
    P3,  N=458, Not yet recruiting, 
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. (Pubmed Central) -  Sep 14, 2024   
    While questions about long-term infant outcomes, the safety of maternal nutrient intake, and the nutrient content of breast milk remain, our findings suggest that semaglutide concentrations in human milk are unlikely to pose clinical concerns for breastfed infants. These results support healthcare providers in making informed decisions regarding postpartum therapeutic interventions.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Reimbursement, US reimbursement, Journal, Medicare:  Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 (Pubmed Central) -  Sep 3, 2024   
    The introduction of highly effective anti-obesity drugs, such as Wegovy, has prompted debate over Medicare's prohibition on coverage of such products...This would increase Medicare spending but would occur regardless of a policy change. Longer-term estimates come with significant uncertainty about utilization and price changes, but these results are consistent with this policy change likely increasing Medicare costs by the low to middle tens of billions of dollars over ten years.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
    Review, Journal:  Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management. (Pubmed Central) -  Sep 3, 2024   
    Agents like liraglutide, semaglutide, and tirzepatide supported by key clinical trials such as Satiety and Clinical Adipose Liraglutide Evidence (SCALE), Semaglutide Treatment Effect in People with Obesity (STEP) program trials, and Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) have demonstrated remarkable efficacy in promoting weight loss and improving metabolic outcomes...The ongoing development of incretin-based therapies and the expanding availability of currently available agents are expected to enhance clinical outcomes further and reduce the burden of obesity-related health complications. This review aims to discuss the mechanisms and efficacy of current and emerging incretin hormone agonists for obesity management.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Euglycemic Ketoacidosis From Semaglutide in a Patient Without Diabetes. (Pubmed Central) -  Sep 2, 2024   
    The incidence of euglycemic ketoacidosis will likely increase with the increasing use of GLP-1 inhibitors, and recognizing the signs and symptoms of this life-threatening condition is essential to treat it effectively. Our literature search identified 1 reported case of euglycemic ketoacidosis in a patient without diabetes associated with tirzepatide but none with semaglutide.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related (Pubmed Central) -  Sep 2, 2024   
    P3
    In the STEP-HFpEF Program echocardiography substudy, semaglutide appeared to improve adverse cardiac remodeling compared with placebo, further suggesting that treatment with semaglutide may be disease modifying among patients with obesity-related HFpEF. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart (Pubmed Central) -  Sep 2, 2024   
    P3
    Treatment with semaglutide led to significant improvements in HF-related symptoms, physical limitations, and exercise function, as well as reductions in weight, CRP, and NT-proBNP in people with and without AF and across AF types. The magnitude of semaglutide-mediated improvements in HF-related symptoms and physical limitations was more pronounced in those with AF vs without AF at baseline.(Research Study to Investigate How Well Semaglutide Works in People Living With Heart
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program. (Pubmed Central) -  Sep 2, 2024   
    P3
    Semaglutide also reduced inflammation, regardless of either baseline CRP or magnitude of weight loss during the trials. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Effects of Semaglutide on Heart (Pubmed Central) -  Sep 2, 2024   
    P3
    These effects were consistent regardless of history of HF. (A Research Study To See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease [FLOW]; NCT03819153).
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide. (Pubmed Central) -  Aug 31, 2024   
    Herein, we describe the first case of skin-limited LCV induced by once-weekly subcutaneous semaglutide in a 73-year-old man with T2DM, who experienced the complete resolution of the skin lesions shortly after the discontinuation of semaglutide therapy. Future prospective studies, adverse event reporting and post-marketing surveillance will certainly contribute to establishing if LCV represents a less rare than expected side effect of both oral and subcutaneous semaglutide formulations.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    A Rare Case of Adult-Onset Nesidioblastosis After Roux-en-Y Gastric Bypass (Exhibit Hall, Cristal Ballroom) -  Aug 28, 2024 - Abstract #CAP2024CAP_226;    
    Her symptoms were not alleviated with medical management (acarbose, diazoxide) or reversal of the gastric bypass...She was placed on Ozempic for weight loss management...In patients with nesidioblastosis and a history of bariatric surgery, use of GLP-1 agonists should be carefully considered. Integrating clinical, biochemical, and histologic findings are crucial to achieving this diagnosis.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Late Facial Edema After Lip Filling With Hyaluronic Acid: Possible Association With the Use of Ozempic. (Pubmed Central) -  Aug 27, 2024   
    The etiology of late inflammatory reactions is unclear and we believe that some medications may be capable of initiating these immune responses. Hyaluronidase is an effective treatment to reverse adverse reactions from hyaluronic acid injection, dissolving the peptide bond proteins within the hyaluronic acid, increasing the viscosity of the material and allowing it to be dispersed throughout the soft tissue.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    P3 data, Journal:  Efficacy and safety of once-weekly semaglutide 2 (Pubmed Central) -  Aug 22, 2024   
    P3
    In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2 Semaglutide 2
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Awiqli (insulin icodec) / Novo Nordisk
    Journal:  Novel Agents in the Management of Diabetes and Risk of Worsening Diabetic Retinopathy. (Pubmed Central) -  Aug 16, 2024   
    For most patients being considered for treatment with a novel anti-hyperglycemic agent, benefits on systemic metabolic and cardiovascular health are very likely to outweigh potential retinal harms. Although the true risks of the new agents on DR are unclear since their safety data come from secondary endpoints, the most vulnerable patients are those with pre-existing high-risk DR, poor baseline glycemic control and using insulin.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) (clinicaltrials.gov) -  Aug 15, 2024   
    P2,  N=84, Recruiting, 
    Although the true risks of the new agents on DR are unclear since their safety data come from secondary endpoints, the most vulnerable patients are those with pre-existing high-risk DR, poor baseline glycemic control and using insulin. Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
    Review, Journal:  Table: GLP-1 and GIP/GLP-1 receptor agonists for chronic weight management. (Pubmed Central) -  Aug 13, 2024   
    Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025 No abstract available
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Hidden Dangers in Patients taking Semaglutide (Ozempic) (Exhibit Hall) -  Aug 6, 2024 - Abstract #ASA2024ASA_4840;    
    There is also a lack of consensus in perioperative guidelines. Here, we discuss the pharmacokinetics of semaglutide, our medically challenging case involving a patient taking semaglutide, and strategies to mitigate risk of pulmonary aspiration.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Ozempic Vs. NPO: Postpone Or Not Postpone? (Exhibit Hall) -  Aug 6, 2024 - Abstract #ASA2024ASA_4605;    
    On the day of surgery, gastric ultrasound showed residual food in her stomach. The case was postponed, and her case was done 3/28 after being off Ozempic for 1 week with a clear liquid diet the day before surgery, and being NPO for 8 hours prior to surgery.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal, FDG PET:  FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue. (Pubmed Central) -  Aug 5, 2024   
    Clinicians should be aware of the presence of these drugs and their potential effect on biodistribution in FDG PET. Further study is needed to best understand the effects of these medications on FDG biodistribution.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
    Retrospective data, Journal, Real-world evidence, Adherence, Real-world:  Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. (Pubmed Central) -  Aug 1, 2024   
    This GLP-1 weight loss treatment real-world analysis, among obese individuals without diabetes, found poor 1-year persistence and adherence and low rates of switching between products. These findings will aid in assessing products cost-effectiveness, understanding obesity care management program needs, forecasting future GLP-1 use and cost trends, and negotiating GLP-1 pharmaceutical manufacturer value-based purchasing agreements.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial. (Pubmed Central) -  Jul 31, 2024   
    P3
    Participants receiving semaglutide were more likely to move to a lower KDIGO risk category (odds ratio: 1.69; 95% CI: [1.32-2.16]) and less likely to move to a higher KDIGO risk category versus placebo (odds ratio: 0.71; 95% CI: [0.59-0.86]). Once weekly semaglutide versus placebo reduced risks of kidney disease end points and improved risk categories irrespective of baseline KDIGO risk.